scholarly journals The Effect of Long-Term Second-Generation Antipsychotics Use on the Metabolic Syndrome Parameters in Jordanian Population

Medicina ◽  
2019 ◽  
Vol 55 (7) ◽  
pp. 320
Author(s):  
Abo Alrob ◽  
Alazzam ◽  
Alzoubi ◽  
Nusair ◽  
Amawi ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Second Generation ◽  
Systolic Pressure ◽  
Clinical Information ◽  
P Value ◽  
Glucose Levels ◽  
The Metabolic Syndrome ◽  
Second Generation Antipsychotics ◽  
Continuous Use

Objectives: The aim of this study was to determine the incidence of metabolic syndrome in patients treated with second-generation antipsychotics (SGAs). Methods: In this retrospective study, we reviewed patients’ electronic medical records (EMRs) of all patients who received one SGA for at least six months, excluding patients who were taking other medications that are associated with significant effect on metabolic syndrome. Relevant clinical information was collected prior to starting the SGA and after six months of continuous use of the same SGA. Results: A total of 91 patients were included in the study. The majority of patients (72%) were diagnosed with schizophrenia. After six months of taking the SGA, 44% of patients experienced elevated systolic pressure, 54.9% had elevated triglyceride, and 31.9% had impaired glucose levels (p value < 0.05). Prior to initiating SGA therapy, 14.3% of patients had metabolic syndrome, while 37.4% had metabolic syndrome after six months of therapy, and it was more prominent in males compared to female patients (p value < 0.05). Conclusion: This study found a strong correlation between SGA use and the appearance of metabolic alterations, such as weight gain, glucose intolerance, and increased triglyceride levels. These findings highlight the importance of assessing metabolic deregulations to minimize SGA associated metabolic abnormalities.

scholarly journals Second Generation Antipsychotics (SGAs) in Schizophrenic Patients and Bipolar Disorder: Correlation With Metabolic Syndrome (NCEP ATP III(a))

2018 ◽  
Vol 11 (1) ◽  
pp. 28
Author(s):  
Consuelo Roldan Menco ◽  
Anderson Díaz-Pérez ◽  
Zoraida Barrios Puerta
Keyword(s):  
Metabolic Syndrome ◽  
Bipolar Disorder ◽  
Second Generation ◽  
Mental Illnesses ◽  
Abdominal Circumference ◽  
High Density Lipoproteins ◽  
P Value ◽  
Antipsychotic Treatment ◽  
The Metabolic Syndrome ◽  
Second Generation Antipsychotics

INTRODUCTION: The Metabolic Syndrome is a set of diverse clinical situations such as diabetes mellitus, hypertension and dyslipidemia. Patients with mental illnesses such as schizophrenia or bipolar disorder have a higher mortality than the general population attributable in 60% to somatic diseases and metabolic syndrome, where second generation antipsychotics increase the risk of weight gain and insulin resistance. Objectives. Correlate the treatment with second generation antipsychotics (SGAs) as a possible predictor for Metabolic Syndrome according to the NCEP ATP III (a) classification. METHODS: Descriptive, cross-sectional correlational study. The sample was of 92 patients, applying an open and convenience sampling due to the mental state of the patients in order to determine their degree of acceptance to the study (Informed Assent) and consent to the legal guardian as the main inclusion criterion. For the analysis, the following variables were considered: blood pressure, weight, height, abdominal circumference, serum levels of triglycerides, glucose and high density lipoproteins. The SPSS 20.0 &reg; program was used logistic regression analysis with a p-value &lt;0.05 and a confidence level of 95%. RESULTS: SGAs most used was clozapine (54.3%). The correlation analysis showed that sociodemographic aspects such as personal history, habits, physical activity and paraclinical and anthropometric records correlated with the possible diagnosis of metabolic syndrome (p &lt;0.05), but not with SGAs (p&gt; 0.05). ). CONCLUSION: No correlation was found between the presence of the metabolic syndrome and the type of antipsychotic treatment.

Second-generation antipsychotics and the metabolic syndrome in drug-naive adolescents

2016 ◽  
Vol 33 (S1) ◽  
pp. s263-s263
Author(s):  
C. Sjo ◽  
N. Bilenberg
Keyword(s):  
Metabolic Syndrome ◽  
Second Generation ◽  
Fasting Blood Glucose ◽  
Child And Adolescent Psychiatry ◽  
First Year ◽  
The Metabolic Syndrome ◽  
Second Generation Antipsychotics ◽  
Naturalistic Setting ◽  
Drug Naïve ◽  
Competing Interest

IntroductionPoor physical health and shorter life expectancy often follows from mental illness. If the disorder starts in childhood/adolescence, the risk of this outcome is even higher. Second generation antipsychotics (SGAs) are suspected to increase cardiovascular risk factors through the development of the metabolic syndrome.ObjectiveWe investigated all the aspects of the metabolic syndrome in drug-naive youth, over a period of 12 months of treatment with SGAs.AimsThis study examines drug-naive youth in their first year of treatment with SGAs, and the possible development of markers of the metabolic syndrome, in a naturalistic setting. We also look at aspects of the patient's disease and environment that may predict which patients are the most at risk for these metabolic derangements.MethodsThirty-five drug-naive adolescents were recruited after their contact with the Psychosis Team at Department of Child and Adolescent Psychiatry in Odense, Denmark. Measurements were taken at different times over the course of their first year of treatment. The markers included, among others: body mass index, waist circumference, blood pressure, fasting blood glucose, as well as high density, low density and total cholesterol. Factors of the patients’ lifestyle and development were recorded as well.ResultsThe results will be presented at the EPA March 2016 in Madrid.ConclusionsThis is, to our knowledge, the first study to include all of the aforementioned aspects in drug-naive adolescents over a 12-month period. Because of this, it may provide us with a unique insight into how, and in which patients, these metabolic changes develop.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals Endogenous hypercortisolism in the patient with obesity: the cause or a competing disorder

2016 ◽  
Vol 13 (1) ◽  
pp. 57-61
Author(s):  
Zhanna E. Belaya ◽  
Aleksandr V. Vorontsov ◽  
Aleksandr V. Il'in ◽  
Andrey Y. Grigor'ev ◽  
Lyudmila Y. Rozhinskaya
Keyword(s):  
Metabolic Syndrome ◽  
Weight Gain ◽  
Clinical Manifestations ◽  
Uncontrolled Hypertension ◽  
Adrenal Tumors ◽  
Glucose Levels ◽  
The Metabolic Syndrome ◽  
High Prevalence ◽  
Neurosurgical Treatment

Endogenous hypercortisolism (EH) is a rare endocrine disorder, one of the most frequent manifestations of which is obesity. Due to the high prevalence of the metabolic syndrome and the similarity of the clinical manifestations, EH may remain undiagnosed. However, prompt diagnosis and treatment can effectively promote complete cure of the patient. We describe the clinical case of a patient К., 58 years old, who suffered from morbid obesity, diabetes, uncontrolled hypertension and dyslipidemia. The CT examination revealed bilateral adrenal incidentalomas. The further follow-up let us to establish Cushing's disease. The adrenal tumors in this case may be the results of a long-term stimulation of the adrenal glands by ACTH. There is a possibility that the first manifestation of the disease began at the age of 30 years after the second pregnancy, when she observed weight gain and poorly controlled hypertension. When remission was achieved after neurosurgical treatment, we could observe significant improvements (reduction in body weight of 10 kg, improved glucose levels), but without the full normalization of all complications and symptoms.Conclusion: EH may cause the development of obesity and metabolic syndrome or significantly exacerbate its course. In cases of doubt, weight gain and poorly controlled manifestations of metabolic syndrome screening is justified to exclude EH.

Prevalence of the metabolic syndrome in women with a previous diagnosis of polycystic ovary syndrome: long-term follow-up

2011 ◽  
Vol 96 (5) ◽  
pp. 1271-1274 ◽  
Author(s):  
Miriam Hudecova ◽  
Jan Holte ◽  
Matts Olovsson ◽  
Anders Larsson ◽  
Christian Berne ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Ovary Syndrome ◽  
The Metabolic Syndrome ◽  
Previous Diagnosis ◽  
Long Term Follow Up

Metabolic Abnormalities in Hypertensive patients and their Risk Factors

2021 ◽  
Vol 15 (7) ◽  
pp. 1494-1496
Author(s):  
M. Imran Ashraf ◽  
Shazana Rana ◽  
M. Salee Makhtar ◽  
Adnan Afzal ◽  
Bushra Suhail ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Selection Criteria ◽  
Hdl Cholesterol ◽  
Serum Glucose ◽  
P Value ◽  
Qualitative Variable ◽  
Hypertensive Patients ◽  
The Metabolic Syndrome ◽  
Gender Based ◽  
Basic Features

Background: Metabolic syndrome is a disorder which is categorized by the presence of various features like hypertension, obesity, insulin resistance and dyslipidemia. One of the basic features of this syndrome is hypertension that may lead to increased incidence of cardiovascular incidents. Aim: To determine the gender based comparison of metabolic syndrome among the hypertensive patients who reported in the outpatient department. Study Time: The present study was conducted from January 2019 to June 2019 over a period of six months. Methods: Known hypertensive patients aged between 20 to 50 years who fulfilled the selection criteria were included in this study. After informed written consent, the physical examination and required laboratory investigation were done. The data was entered and analysed by using SPSS version 23 Mean±standard deviation was recorded for the quantitative variables while frequency was utilized for the qualitative variable. The p-value of ≤0.05 was taken as significant. Results: A total of 85 known patients of hypertension were included in the study comprising (70.12%) males and (35.40%) females. They were evaluated for the metabolic syndrome using the Adult Treatment Panel III- A (ATP –III A) criteria. Their blood pressure was recorded and fasting blood sample were taken to determine the levels of serum glucose, HDL-cholesterol and triglyceride. Conclusion: Metabolic syndrome is more prevalent in the hypertensive patients Keywords: Metabolic syndrome, Hypertension, Dyslipidemia

The metabolic syndrome in long-term cancer survivors, and important target for secondary preventive measures

2002 ◽  
Vol 28 (4) ◽  
pp. 195-214 ◽  
Author(s):  
Janine Nuver ◽  
Andries J Smit ◽  
Aleida Postma ◽  
Dirk Th Sleijfer ◽  
Jourik A Gietema
Keyword(s):  
Metabolic Syndrome ◽  
Cancer Survivors ◽  
Preventive Measures ◽  
The Metabolic Syndrome ◽  
Important Target
Sign in / Sign up

Export Citation Format

Share Document